LACE+ and MRS Score Readmission Rate Assessment

NCT04365673 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-03-17

No results posted yet for this study

Summary

A study to demonstrate that the LACE+ score in non-inferior to the medication risk score when predicting 30-day readmission post hospital discharge.

Conditions

  • Hospitalism

Interventions

OTHER

Pharmacist transition of care consultation

Pharmacist-delivered comprehensive medication review

Sponsors & Collaborators

  • Tabula Rasa HealthCare

    lead INDUSTRY

Principal Investigators

  • Jennifer Bingham, PharmD · Tabula Rasa HealthCare

Eligibility

Min Age
18 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-07
Primary Completion
2021-03-01
Completion
2021-03-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04365673 on ClinicalTrials.gov